0
Obstructive Lung Diseases: COPD Pharmacotherapy |

Effects of Aclidinium on Nocturnal Oxygen Saturation of COPD Patients (B-C Stages)

Giuseppe Fiorentino, PhD; Anna Annunziata, PhD; Gianfranco Scotto di Frega, PhD; Rosa Cauteruccio, PhD; Antonella Marotta, PhD; Mariantonietta Mazza, PhD
Author and Funding Information

Monaldi Hospital, Naples, Italy


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A388. doi:10.1016/j.chest.2016.02.403
Text Size: A A A
Published online

Extract

SESSION TITLE: COPD Pharmacotherapy

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To evaluate the effectiveness of the aclidinium bromide (322 mcg twice a day) in improving nocturnal oxygen saturation in COPD patients (B-C stages).

METHODS: We examined 100 patients, all affected by the same COPD severity according to GOLD guidelines (B-C stages). All patients, at the enrolment, filled in a questionnaire on the presence of the following symptoms: a) excessive daytime sleepiness; b) choking or gaspingduring sleep; c) recurrent awakenings from sleep; d) unrefreshing sleep; e) daytime fatigue; f) morning headaches; g) nicturia. We studied the nocturnal oxygen saturation of patients who presented symptoms. 45 patients had sleep disordered breathing with desaturation. All 45 patients were treated aclidinium bromide (322 mcg twice a day). Patients were re-evaluated after 15 days of treatment.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543